Sygnature CEO, Simon Hirst has announced the successful completion of another hit-to-lead program, this time with biotechnology company, Chroma Therapeutics Ltd.

Chroma’s CEO, Ian Nicholson reflected, “With the aid of Sygnature Chemical Services, Chroma has been able to make rapid and substantial progress in several areas of our research. In particular, the two companies have collaborated to find candidates against a challenging inflammation target. The contribution of the Sygnature group has enabled us to move from a hit molecule to a substantial portfolio of potential lead molecules within a nine month period. Sygnature has provided us with an incremental and flexible resource to support our in-house discovery efforts, well-versed in modern medicinal chemistry techniques and with an ability to make a high quality intellectual contribution to the project. This, in addition to the open and efficient interaction between both company’s scientists, led to the meeting of very aggressive timelines. On this basis we very much see Sygnature as a leading provider of chemical services.”

Chroma Therapeutics is a privately-held biotechnology company focused on harnessing the power of chromatin biology and novel drug accumulation approaches to discover and develop a new generation of targeted cancer and inflammation treatments.
(www.chromatherapeutics.com)